CRNX Live signaler | Maksimer profitt med Getagraph.com

KJøP 104628 min ago

@ $36.22

Utstedt: 14 feb 2024 @ 21:47

Avkastning: 16.29%

Forrige signal: feb 14 - 18:28

Forrige signal: Selg

Avkastning: -0.41 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	551 185
Gjennomsnittsvolum	798 153
Markedsverdi	3.28B
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-0.840 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.41
ATR14	$0.0550 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Struthers Richard Scott	Sell	350	Common Stock
2024-04-15	Pizzuti Dana	Sell	14 375	Stock option (Right to Buy)
2024-04-15	Pizzuti Dana	Buy	14 375	Common Stock
2024-04-15	Pizzuti Dana	Sell	14 375	Common Stock
2024-04-15	Struthers Richard Scott	Buy	20 000	Common Stock

INSIDER POWER
20.03
Last 99 transactions
Buy: 1 532 159 \| Sell: 1 109 365

Volum Korrelasjon

Lang: -0.22 (neutral)

Kort: 0.79 (moderate)

Signal:(66.221) Neutral

Crinetics Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
VYNE	0.883
CPIX	0.875
FULC	0.871
ARWR	0.869
RDUS	0.866
LITM	0.861
RNDM	0.858
SPRO	0.857
JAKK	0.844
ENTA	0.841

10 Mest negative korrelasjoner
ALGM	-0.894
SITM	-0.856
GMII	-0.853
PPBT	-0.85
GDRX	-0.835
UMPQ	-0.821
GFS	-0.815
SBBP	-0.801

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Crinetics Pharmaceuticals Korrelasjon - Valuta/Råvare

0.71
( moderate )

0.56
( weak )

0.00
( neutral )

0.08
( neutral )

-0.04
( neutral )

-0.27
( neutral )

Crinetics Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$4.01M
Bruttogevinst:	$2.92M (72.64 %)
EPS:	$-3.69

FY	2023
Omsetning:	$4.01M
Bruttogevinst:	$2.92M (72.64 %)
EPS:	$-3.69

FY	2022
Omsetning:	$4.74M
Bruttogevinst:	$3.35M (70.68 %)
EPS:	$-3.08

FY	2021
Omsetning:	$1 078.00
Bruttogevinst:	$1 078.00 (100.00 %)
EPS:	$-0.00280

Financial Reports:

No articles found.

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Sanntidsoppdatering for Crinetics Pharmaceuticals [CRNX]

Upcoming Earnings Alert